Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 1.00 |
| ▸ | ESR1 | P03372 | 12/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286186 | 0.94 | ESR1 (1.00) | ESR2ESR1MMP3BCL2L1 | |
| SCHEMBL6286195 | 0.91 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL6283895 | 0.88 | ESR2 (1.00) | ESR2ESR1ALOX5 | |
| SCHEMBL6286158 | 0.82 | ESR1 (0.75) | ESR2ESR1 | |
| SCHEMBL6283932 | 0.81 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL22568966 | 0.66 | ESR2 (0.49) | ESR2ESR1ALOX5MMP3BCL2L1 | |
| SCHEMBL6794599 | 0.65 | ESR2 (0.49) | ESR2ESR1DRD2DRD1 | |
| SCHEMBL6282618 | 0.64 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL22568910 | 0.64 | ESR1 (0.47) | ESR2ESR1ALOX5DRD2DRD1 | |
| SCHEMBL12009549 | 0.63 | ESR1 (0.52) | ESR2ESR1MMP3BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838584-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040162304-A1 | Estrogen receptor modulators | MERCK & CO., INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162304-A1 | Estrogen receptor modulators | ESRRA, GPER1, ESRRB | ESR2 4/4885ESR1 5/4885ALOX5 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.